Toward the end of 2023, the economy started showing signs of stabilization and easing inflationary pressure as the Fed finally decided to keep interest rates unchanged. This is likely to benefit generic drugmakers like Amphastar Pharmaceuticals (AMPH) , Teva Pharmaceutical (TEVA) and Dr. Reddy’s Laboratories (RDY) , who can potentially benefit from declining costs in the long run.These drugmakers are also focusing on new product launches or existing products with high gross margins to support their top and ...

Investors seeking healthy returns should add stocks with favorable liquidity to their portfolios.Liquidity measures a company’s capability to meet its short-term debt obligations. Stocks with high liquidity levels have always been in demand, owing to their potential to provide maximum returns.Investors should be alert before considering such stocks. While a high liquidity level may imply that the company is clearing its dues faster than its peers, it may also suggest that it cannot utilize assets competentl ...

The most recent trading session ended with Amphastar Pharmaceuticals (AMPH) standing at $54.03, reflecting a -1.44% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.07%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 11.19% over the past month. This has lagged the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98% in that time.Market participants will be closely following the financial results of Amphastar Pharmace ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Dan Dischner - SVP of Corporate Communications Bill Peters - CFO Conference Call Participants Glen Santangelo - Jefferies Tim Chiang - Capital One Operator Greetings and welcome to the Amphastar Pharmaceuticals Third Quarter Earnings Conference Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) 11570 6 th Street Rancho Cucamonga, CA 91730 (Address of principal executive offices) (zip code) (909) 980-9484 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications Bill Peters - Chief Financial Officer & Executive Vice President, Finance Tony Marrs - Executive Vice President, Regulatory Affairs & Clinical Operations Conference Call Participants Tim Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings and welcome to the Amphastar Pharmaceuticals Second Quarter Ear ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |----------------------------------------------------------------------------------------------------- ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Dan Dischner - VP of HR & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants Tim Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |---------------------------------------------------------------------------------------------------- ...

Injectables Proprietary Biosimilars Complex Generic Inhalation Corporate Presentation Needham Conference April 2023 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including, but not limited t ...